Aktis Oncology, Inc. reported results
SEC 8-KRead source ↗
Aktis Oncology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$9.1
Growth cash-flow model
Base case. Range ~$9.1–$9.2. Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability.
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Aktis Oncology, Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders6 buying, 3 selling9 purchases and 11 sales by directors and officers, last 12 monthsInsider trades
- Funds78 adding, 24 cuttingOf 18 active managers that changed their stake, 8 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Aktis Oncology, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 68% and a beta of 1.6 against the S&P 500.
- Heavily shorted. 26.7% of the shares available to trade are sold short (8.4 days of average volume to cover).
Latest results
- Earnings per share
- -$0.44 against an average estimate of -$0.43: missed by 2.1%
- Share reaction
- +3.9% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
- Next report
- November 12, 2026; average EPS estimate -$0.45
Price chart
- 1 day-8.4%
- 1 week-7.2%
- 1 month-21.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 13, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
- Insider trade
Czibere Akos (Chief Medical Officer) sold $1.4M of stock
SEC Form 4 - Insider trade
Ron-Bigger Shulamit (Chief Operating Officer) sold $1.4M of stock
SEC Form 4
Valuation models
We value Aktis Oncology, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$9.1 ~$9.1–$9.2 | Primary model, counts double |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$0.6 ~$0.6–$2.3 | Left out: out of range vs price (0.04x) |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$9.1 ~$9.1–$9.2 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Aktis Oncology, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026, after the close. Analysts expect revenue of $2m and EPS of −$0.45 (range −$0.56 to −$0.34) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.68 | +98% | $11m | +64% |
| Next | −$2.14 | −27% | $10m | −3% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +3.6% on 90 days ago. In the last 30 days, 1 analyst raised Aktis Oncology, Inc.'s forecast and 3 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$1.62 | −$1.97 |
| 60 days ago | −$1.72 | −$2.12 |
| 30 days ago | −$1.69 | −$2.15 |
| 7 days ago | −$1.69 | −$2.15 |
| Now | −$1.68 | −$2.14 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.43 | −$0.44 | −2.1% |
| Mar 2026 | −$0.33 | −$0.38 | −15.2% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 26.7% of tradable shares
- Days to cover
- 8.44 at average volume
- Short interest, 1 month
- +33% to October 15, 2026
- Held by institutions
- 73% of shares
- Held by insiders
- 14.1% of shares
- Employees
- 79 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- −28.4%
- vs 200-day average
- −30.5%
- Volatility (1 year)
- 68%
- Beta vs S&P 500
- 1.62
Share price after results
- Next day
- 3 up, 0 down typical move ±9.3%
- After a week
- 2 up, 1 down typical move ±3.4%
- After a month
- 1 up, 2 down typical move ±8.9%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 13, 2026 | +3.9% | +0.5% | 0.0% | −3.5% |
| May 11, 2026 | +6.1% | +0.1% | +0.1% | −0.1% |
| March 30, 2026 | +17.8% | +2.6% | +10.1% | +23.2% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $1.1B
- Institutions reporting
- 114
- Shares held vs prior quarter
- ▼ 2.9%
- Positions opened / closed
- 51 / 6
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Mpm Bioimpact LLC | $156M | 4.8M | 14.2% | 0.0% |
| Ecor1 Capital, LLC | $155M | 4.8M | 14.1% | 0.0% |
| Blue Owl Capital Holdings LP | $99M | 3.1M | 9.0% | ▼ 2.9% |
| Blackrock, Inc. | $73.4M | 2.3M | 6.7% | ▲ 7.9% |
| T. Rowe Price Investment Management, Inc. | $66.1M | 2.1M | 6.0% | ▼ 3.4% |
| Wellington Management Group LLP | $63.4M | 2.0M | 5.8% | ▼ 15.1% |
| RTW Investments, LP | $51.3M | 1.6M | 4.7% | 0.0% |
| RA Capital Management, L.P. | $42.4M | 1.3M | 3.8% | ▼ 12.6% |
| Jupiter Topco LLC | $42.4M | 1.3M | 3.8% | — |
| Baker Bros. Advisors LP | $32.1M | 996K | 2.9% | 0.0% |
| Octagon Capital Advisors LP | $31M | 961K | 2.8% | 0.0% |
| Merck & Co., Inc. | $30.7M | 953K | 2.8% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Aktis Oncology, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $114M 9 trades by 6 insiders, last 12 months Insider sales History → $3.2M 11 trades by 3 insiders · 8% under pre-set plans
Net ▲ $111M net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Czibere Akos Chief Medical Officer | September 23, 2026 | Sell pre-set plan | 7,401 | $21.03 | $155,643 |
| Czibere Akos Chief Medical Officer | September 23, 2026 | Sell pre-set plan | 5,099 | $20.19 | $102,949 |
| Herrmann Ken Director | July 20, 2026 | Sell | 3,506 | $24.56 | $86,107 |
| Herrmann Ken Director | July 20, 2026 | Sell | 1,350 | $24.56 | $33,156 |
| Herrmann Ken Director | July 17, 2026 | Sell | 3,065 | $25.21 | $77,269 |
| Czibere Akos Chief Medical Officer | July 8, 2026 | Sell | 4,371 | $28.71 | $125,491 |
| Czibere Akos Chief Medical Officer | July 8, 2026 | Sell | 30,829 | $27.95 | $861,671 |
| Czibere Akos Chief Medical Officer | July 8, 2026 | Sell | 14,800 | $27.13 | $401,524 |
| Ron-Bigger Shulamit Chief Operating Officer | July 8, 2026 | Sell | 15,800 | $27.13 | $428,654 |
| Ron-Bigger Shulamit Chief Operating Officer | July 8, 2026 | Sell | 30,000 | $27.94 | $838,200 |
| Ron-Bigger Shulamit Chief Operating Officer | July 8, 2026 | Sell | 4,200 | $28.75 | $120,750 |
| Kim Helen Susan Director | January 12, 2026 | Buy | 812,455 | $18.00 | $14.6M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- August 13, 2026
- May 11, 2026
- March 30, 2026
Recent SEC filings
- 10-Q Quarterly report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-K Annual report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Aktis Oncology, Inc. in brief
- What does Aktis Oncology, Inc. do?
- Aktis Oncology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Aktis Oncology, Inc.'s stock ticker?
- Aktis Oncology, Inc. trades under the ticker AKTS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Aktis Oncology, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Mpm Bioimpact LLC, Ecor1 Capital, LLC and Blue Owl Capital Holdings LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Aktis Oncology, Inc. stock?
- Over the last 12 months, Aktis Oncology, Inc.'s directors and officers reported 9 open-market purchases and 11 sales on Form 4. The insider trading page charts every trade.
- When is Aktis Oncology, Inc.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Aktis Oncology, Inc. announces its own schedule.
Follow research on Aktis Oncology, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.